MedTrace Logo

Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia

NCT04679285 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2025-12-23

No results posted yet for this study

Summary

Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation.

This pilot study aims to evaluate the minimal residual disease on ovarian fragments harvested before allogeneic stem cell transplantation at the time of complete remission.

Conditions

Sponsors & Collaborators

  • Canceropôle Nord Ouest

    collaborator OTHER

  • Saint-Louis Hospital, Paris, France

    collaborator OTHER

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Laurène Fenwarth, MD · University Hospital, Lille

Eligibility

Min Age
2 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2022-09-04
Completion
2022-09-04

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679285 on ClinicalTrials.gov